topic

1195 Discovery of CBO421, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer
Simon Dohrmann, James Levin, Nicholas Dedeic, Amanda Almaguer, Doug Zuill, Elizabeth Abelovski, Rajvir Grewal, Joanne Fortier, Qiping Zhao, Maria Hernandez, Karin Amundson, Madison Moniz, Hongyuan Chen, Dhanya Panicker, Thanh Lam, Thomas P Brady, Allen Borchardt, Jason N Cole, Leslie W Tari

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1318; DOI: 10.1136/jitc-2023-SITC2023.1195
1196 GDF-15 neutralizing antibody visugromab increases intratumoral immune cell infiltration to support bispecific T-cell engagers
Sabrina Genssler, Daniel Schaetzlein, Eugen Leo, Markus Haake, Christine Schuberth-Wagner

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1319; DOI: 10.1136/jitc-2023-SITC2023.1196
1197 Site-specific anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy via enhancement of T cell penetration and engagement
Yunfeng Pan, Qi Xue, Tao Shi, Hanbing Wang, Xueru Song, Jie Li, Jia Wei

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1320; DOI: 10.1136/jitc-2023-SITC2023.1197
1198 Cytokine affinity tuning and antibody discovery/optimization using the AlphaSeq and AlphaBind platforms to generate targeted immuno-oncology therapeutics
Davis Goodnight, Kimberly Wellman, John Marken, Jeff Adamo, Emily Engelhart, Oliver Serang, Aditya Agarwal, Cameron Cordray, Samer Halabiya, Kyle Minch, Ryan Swanson, Randolph Lopez

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1321; DOI: 10.1136/jitc-2023-SITC2023.1198
1199 Identifying a source of dysfunctional CAR T cells incorporating with PBMC scRNA-seq data in patients with Non-Hodgkin Lymphoma
Changjin Hong, Yoon Ho Choi, David Wald, Tae Hyun Hwang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1322; DOI: 10.1136/jitc-2023-SITC2023.1199
1200 Leveraging the immunocompetent Vk*MYC^hCRBN model of multiple myeloma to determine and overcome T cell engager antibody resistance mechanisms
Erin W Meermeier, Caleb Stein, Meaghen Sharik, Megan Du, Chang-Xin Shi, Yuan Xiao Zhu, Keith Abayasiriwardana, Timothy Fisher, Bas Baaten, Natalie Bezman, Kristin Bompiani-Myers, P Leif Bergsagel, Marta Chesi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1323; DOI: 10.1136/jitc-2023-SITC2023.1200
1201 Collagen binding TNF reduces systemic toxicity and drives complete remission of established immunologically cold murine tumours
Pooja Kaur, Jun Ishihara

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1324-A1325; DOI: 10.1136/jitc-2023-SITC2023.1201
1202 In vivo engineering of CAR T cells using a novel targeted LNP-mRNA technology
Gregor Adams, Ferran Soldevila, Daiki Matsuda, Yan Zhang, Yanjie Bao, Brittany Ross, Stuart A Sievers, John Li, Michael Peel, Michelle Nguyen, Barzan A Sadiq, Josephine Nguyen, Theresa Hunter, Claudia Fernandez, Yi Kuo, James Vestal, Matthew Butcher, Jeffrey Chen, Stanley Zhang, Duy Nguyen, Makan Khoshnejad, Donald Jhung, Steve Tanis, Michael Rosenzweig, Priya Karmali, Adrian Bot, Haig Aghajanian

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1326; DOI: 10.1136/jitc-2023-SITC2023.1202
1203 Targeted in vivo generation of CAR T and NK cells utilizing an engineered lentiviral vector platform
James I Andorko, Ronnie M Russell, Bruce C Schnepp, Ramesh Singh, Debasish Boral, Philip R Johnson

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1327; DOI: 10.1136/jitc-2023-SITC2023.1203
1204 In-situ reprograming of cancer cells to cDC1s elicits complete tumor regression and immune memory as monotherapy
Ervin Ascic, Fritiof Åkerström, André Rosa, Malavika Nair, Olga Zimmermannova, Emilie Renaud, Xiaoli Huang, Cristiana Pires, Fábio Rosa, Carlos-Filipe Pereira

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1328; DOI: 10.1136/jitc-2023-SITC2023.1204

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages